Cencora (COR) Set to Release Earnings on Wednesday

Cencora (NYSE:COR) is expected to be releasing its Q4 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $4.58 per share and revenue of $87.95 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The company had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. During the same period in the previous year, the firm earned $4.00 earnings per share. Cencora’s revenue for the quarter was up 5.1% compared to the same quarter last year. On average, analysts expect Cencora to post $17.87 EPS for the current fiscal year and $19.77 EPS for the next fiscal year.

Cencora Stock Performance

Shares of COR opened at $338.00 on Tuesday. The company has a 50-day moving average of $323.74 and a two-hundred day moving average of $317.49. The stock has a market cap of $64.50 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 1.66 and a beta of 0.58. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. Cencora has a one year low of $244.82 and a one year high of $377.54.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Leerink Partners increased their target price on Cencora from $380.00 to $388.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Citigroup reiterated a “buy” rating on shares of Cencora in a report on Thursday, August 6th. UBS Group dropped their price target on Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, October 16th. Robert W. Baird upped their price target on Cencora from $373.00 to $375.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Finally, Weiss Ratings raised Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $368.38.

Insiders Place Their Bets

In other news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This trade represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.38% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.